Bimekizumab Produces Sustained Reductions in Pain and Draining Tunnels in HS Patients
Bimekizumab-bkzx (Bimzelx, UCB) showed sustained improvements in skin pain and resolution of draining tunnels in patients with moderate-to-severe hidradenitis suppurativa (HS), according to three-year data from the BE HEARD trials presented at the Symposium on Hidradenitis Suppurativa Advances (SHSA) 2025 Congress in Nashville, TN.